Sickle cell disease is an inherited disorder of hemoglobin, the oxygen-carrying protein inside red blood cells. In the most severe forms, red blood cells can become rigid and adopt a crescent, or “sickle,” shape. These cells can obstruct small blood vessels, restricting oxygen delivery to tissues and triggering vaso-occlusive crises. Such episodes can produce intense pain and may require hospitalization, intravenous fluids and opioid medication. Over time, the disease can also generate persistent or recurrent pain involving several body regions and different biological mechanisms, including tissue injury, inflammation and changes in how the nervous system processes pain. In children, repeated crises and medical procedures can become frightening experiences. The combination of physical pain, anticipatory anxiety and disrupted routines may contribute to a cycle in which pain increasingly dominates everyday decisions and behavior.

The investigators are focusing on “pain interference,” a measure that captures what pain prevents a person from doing rather than only how severe the pain feels. A child may report moderate pain yet still be unable to attend school, exercise, concentrate, sleep well or participate socially. The primary outcome will be assessed with the Pediatric Item Bank version 2.0 Pain Interference Short Form 8a, part of the Patient-Reported Outcomes Measurement Information System, or PROMIS. The questionnaire asks about the previous seven days and covers physical, emotional, cognitive, social and recreational activities, as well as sleep and enjoyment of life. Scores are converted to a 0-to-100 T-score, with higher values indicating greater interference. In Dutch pediatric reference data, a score of 49 or higher marks a clinically relevant level of difficulty. Children with severe sickle cell disease in previous research averaged a score above that threshold.

The rationale for trying EMDR comes from growing evidence that psychological and biological factors interact in chronic pain. Trauma exposure can affect emotional regulation, increase vigilance and alter pain sensitivity. Pain itself can also become associated with catastrophic mental images, such as fears that the next crisis will be unbearable or life-threatening. These responses may amplify the impact of pain even when the underlying disease activity has not changed. EMDR was originally developed to treat post-traumatic stress disorder. During therapy, a person recalls a disturbing memory while simultaneously following an external stimulus, commonly a therapist’s finger moving from side to side, although sounds or tactile stimulation may also be used. The proposed mechanism is that this dual-attention process helps the brain reprocess distressing memories, weaken their emotional intensity and create more adaptive associations. Researchers stress that EMDR is not intended to remove the genetic cause of sickle cell disease or directly prevent vaso-occlusive crises. Its target is the distress and functional disruption linked to pain and traumatic memories.

The RELAX trial will enroll 40 participants at Amsterdam UMC, with 20 randomly assigned to immediate EMDR and 20 assigned to a waiting-list control group. Eligibility requires a confirmed diagnosis of sickle cell disease, age between 6 and 18 years, sufficient Dutch or English to complete the assessments and a PROMIS Pain Interference score above the clinical cutoff. Children aged 6 or 7 will be assessed through parent reports, while those aged 8 and older will complete self-report measures alongside reports from a parent. Participants will be allocated in a one-to-one ratio using computerized block randomization that accounts for age group and gender. Because the intervention is psychological, neither participants nor therapists can be blinded, but independent outcome assessors will remain unaware of group assignments. The waiting-list group will receive the same EMDR treatment after a nine-week comparison period, allowing all participants eventual access to the therapy.

Treatment will consist of a 90-minute intake session followed by as many as six 60-minute EMDR sessions. During the intake, the psychologist, child and parents will develop a case formulation and identify pain-related and trauma-related memories that remain emotionally disturbing. These may include frightening hospital admissions, invasive procedures or previous crises, as well as “flash-forward” images that depict feared future events. Each target will be ranked using the Subjective Units of Disturbance scale, which ranges from zero, representing no disturbance, to 10, representing the highest disturbance. Therapists will begin with the memory or mental representation carrying the greatest emotional load. The standard EMDR sequence includes history-taking, preparation, assessment, desensitization, installation of adaptive information, a body scan, closure and re-evaluation. Treatment can finish early if distress associated with all relevant targets falls to zero and the child, parents and therapist agree that meaningful improvement has occurred.

The study will measure much more than a single pain score. Secondary outcomes include post-traumatic stress symptoms, anxiety, depressive symptoms, physical mobility, the number of painful days, pain intensity, pain medication use and school absence. Participants will keep a one-week diary before each major assessment, recording pain frequency, pain severity, medication and missed school. Pain intensity will also be rated on a 0-to-10 numerical scale before and after EMDR sessions. Trauma symptoms will be screened with the Child and Adolescent Trauma Screen, a questionnaire based on diagnostic criteria for post-traumatic stress disorder. It includes questions about potentially traumatic events, PTSD symptoms and psychosocial functioning. The investigators will also document themes in pain and trauma memories and conduct a 15-minute interview to determine whether families found the therapy practical, acceptable and manageable.

The planned sample is small, reflecting the relatively limited number of children with sickle cell disease in the Netherlands, but the researchers calculated that 40 participants should provide useful statistical power while allowing for an anticipated 15 percent dropout rate. The trial’s primary comparison will examine PROMIS Pain Interference scores two weeks after the immediate-treatment group finishes EMDR and nine weeks after participants enter the waiting-list group. The main analysis will use linear mixed-effects models, a statistical approach designed to evaluate repeated measurements while accounting for differences between participants and incomplete observations. Analyses will follow the intention-to-treat principle, meaning that all randomized participants will be included regardless of whether they complete treatment. The investigators consider a reduction of 2.25 points on the PROMIS scale to be clinically meaningful for children with sickle cell disease, although the importance of any observed change will also depend on effects on school, mobility, distress and daily activities.

Safety and treatment quality are central to the protocol because asking children to revisit distressing experiences can temporarily increase emotional discomfort. Therapists will be licensed, master’s-level clinical psychologists trained in EMDR through the EMDR European Association. Monthly group supervision will be led by a certified EMDR Europe child and adolescent consultant. With consent, therapy sessions will be recorded for supervision, and a random 10 percent of recordings will be reviewed to assess whether the treatment follows the prescribed protocol. Any undesirable experience will be recorded whether or not it is considered related to EMDR. Children will continue their usual sickle cell medications and clinical care throughout the study, and urgent psychological or medical support will be provided when necessary. The protocol excludes young people with conditions requiring immediate psychiatric intervention, current circumstances that make therapy unsafe, simultaneous trauma treatment with another therapist or major medical complications that could interfere with participation.

The trial is registered at ClinicalTrials.gov as NCT07001631 and was approved by the Amsterdam UMC medical ethics committee. Recruitment is expected to be completed in July 2027, meaning that the scientific community will have to wait for the actual outcome data before judging whether EMDR changes pain interference in this population. The researchers acknowledge that the single-center design and small sample may limit how broadly the findings can be applied, and that participants who need additional psychological care during the trial could complicate comparisons. Even so, the study addresses a neglected question: whether treating the emotional and memory-related consequences of repeated pain can improve function without altering the blood disorder itself. If the intervention produces durable reductions in pain interference at the planned three-month follow-up, it could offer clinicians another tool alongside medication, hematological care and established pain-management strategies. The broader possibility is equally significant: a therapy developed for traumatic memories might help children with other forms of chronic pain regain parts of childhood that illness has placed on hold.

Subject of Research: EMDR therapy for reducing pain interference in children and adolescents with sickle cell disease

Article Title: Effect of EMDR for reduction of pain interference in children with sickle cell disease, the RELAX study: a randomized controlled trial protocol

Article References: Nery, M., Scholten, L., Voorrips, C. et al. “Effect of EMDR for reduction of pain interference in children with sickle cell disease, the RELAX study: a randomized controlled trial protocol.” BMC Pediatrics 26, article 797 (2026). Original research page

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07153-2

Keywords: sickle cell disease, pediatric pain, pain interference, EMDR therapy, chronic pain, post-traumatic stress, randomized controlled trial, PROMIS, children’s health

Through this patient-reported outcome diary, clinical staff have begun to gather more comprehensive data reflecting the individual experiences of sickle cell disease patients. The traditional methods of monitoring pain have often fallen short due to their generic nature, failing to accommodate the variances in pain perception and coping mechanisms. This diary is uniquely tailored to address the specific needs of sickle cell patients, fostering a deeper understanding of their pain management while also empowering them with a sense of agency regarding their health.

The diary’s design encompasses multiple dimensions of pain, including intensity, duration, and emotional implications. Each entry is structured to facilitate the capture of both quantitative data and qualitative insights, allowing healthcare providers to analyze the impact of pain on various aspects of a patient’s life. This comprehensive view is often lacking in prevalent research, creating a gap in effective pain management strategies that adequately address the nuances of patient experiences.

As the chronic pain of sickle cell disease can lead to additional complications, this innovative diary also aims to monitor the psychological impact these crises impose on individuals. Patients often report feelings of isolation and frustration due to their condition; thus, the diary provides a platform for emotional expression. By chronicling both the physical and emotional toll of sickle cell disease, researchers hope this diary will pave the way for better-tailored interventions and treatment plans.

Innovation in monitoring patient-reported outcomes is vital in today’s healthcare landscape. Previous studies have emphasized that incorporating patient perspectives into healthcare systems can enhance treatment efficacy. This diary effort aligns with strategies aimed at patient-centered care, which priorities real-world insights borne from diverse patient experiences. Consequently, this novel approach has significant implications for how healthcare providers understand and treat the complexities of sickle cell disease.

Initial feedback from patients involved in the study indicates that the diary offers therapeutic benefits beyond mere data collection. Patients express relief in being able to articulate their pain experiences—something that traditional methods often overlooked. By articulating their challenges, patients may feel more connected to their self-management processes and more engaged in their treatment plans. This dynamic is crucial as chronic disease management heavily relies on patients remaining proactive and informed about their health.

Furthermore, the diary functions as a powerful communication tool between patients and healthcare providers. It establishes a shared language centered around individual experiences, which enhances consultations and subsequent therapeutic decisions. Importantly, healthcare practitioners can target their approaches more effectively, ensuring that interventions resonate with patients based on their unique pain experiences.

The potential implications of this research extend beyond sickle cell disease treatment. By demonstrating a novel patient-reported outcome diary, this study could serve as a model for managing other chronic pain conditions as well. The framework implemented here can inspire modifications within various healthcare domains, creating a ripple effect that may enhance patient involvement across medical practices.

The science behind the patient-reported outcome diary also should not be overlooked. Researchers designed it based on considerations regarding usability and accessibility, ensuring that all patients, regardless of educational background or technological proficiency, can utilize it effectively. Education initiatives accompanying the launch of the diary will help patients maximize its benefits, equipping them with the necessary skills to comprehensively document their experiences.

This innovation arrives at a crucial time when the healthcare landscape is shifting increasingly towards integrated and personalized approaches to patient care. The data collected through the patient-reported outcome diary will not only bolster academic research into sickle cell disease but also inform potential policy changes aimed at improving pain management protocols. As insights gleaned from real-world experiences proliferate within the healthcare community, clinicians may be motivated to rethink existing paradigms surrounding chronic pain treatment.

Moving forward, researchers are planning larger-scale trials to assess the diary’s efficacy and adaptability across various populations. This next stage will involve collaborations with healthcare institutions, treatment centers, and advocacy groups dedicated to sickle cell awareness. The ultimate goal remains constant: to redefine pain management and enhance the lives of those affected by this often-misunderstood condition.

In conclusion, the development of this patient-reported outcome diary stands as a testament to the power of patient voice in health research. When patients articulate their experiences authentically, not only do they engage more meaningfully in their care, but they also contribute to a body of knowledge that can transform clinical practices and improve health outcomes. As researchers build on this initial foundation, the hope remains that ongoing exploration into patient perspectives will continue to reshape the landscape of chronic pain management across various diseases.

The combination of real-time data, emotional articulation, and patient empowerment revealed through this diary could bring significant change not just for patients with sickle cell disease, but for anyone grappling with chronic pain. As this research progresses, experts anticipate incorporating findings into broader pain management strategies emphasizing the importance of improving quality of life for chronic pain patients.

By fostering deeper connections between patients and providers, implementing innovative solutions like the patient-reported outcome diary can ensure that health outcomes are reflective of the thorough realities faced by those managing complex chronic conditions. As healthcare systems evolve, prioritizing real patient experiences will remain crucial, making the potential of this diary and its findings a noteworthy focus for the future of healthcare.

Subject of Research: Sickle Cell Disease and Pain Management

Article Title: Development of a Novel Patient-Reported Outcome Diary to Capture and Monitor Home-Managed Pain Crises in Patients with Sickle Cell Disease

Article References:

Turnbull, J., Williams, B., Myrick, S. et al. Development of a Novel Patient-Reported Outcome Diary to Capture and Monitor Home-Managed Pain Crises in Patients with Sickle Cell Disease.
Adv Ther (2026). https://doi.org/10.1007/s12325-025-03473-4

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12325-025-03473-4

Keywords: Sickle Cell Disease, Chronic Pain, Patient-Reported Outcomes, Pain Management, Health Innovation.

Sickle cell disease, the most prevalent inherited red blood cell disorder in the United States, affects approximately 100,000 individuals, with a disproportionate impact on African American communities where one in every 365 births is affected. The disease is characterized by the production of abnormally shaped hemoglobin S, leading to the classic sickle-shaped erythrocytes. These malformed cells obstruct microvascular blood flow, precipitating episodes of intense ischemic pain, or VOC, which not only cause severe discomfort but also elevate the risk of end-organ damage and infection, making timely and effective pain management essential in emergency care settings.

The study, led by Dr. Abdulaziz Abu Haimed at the University of Maryland Medical Center, scrutinizes the adherence to the National Heart, Lung, and Blood Institute (NHLBI) and American Society of Hematology (ASH) guidelines concerning the assignment of ESI scores and corresponding pain treatment timelines. The ESI is a standardized triage tool used across emergency departments in the U.S., ranging from 1, denoting the highest urgency, to 5, marking the lowest. For patients with VOC, guidelines recommend an ESI score of 2, signifying a high-acuity case meriting rapid intervention, with expectations for the first analgesic dose within an hour of arrival.

Through a retrospective examination of 125 sickle cell-related emergency visits over six months, the researchers isolated 66 VOC visits, excluding those complicated by coexisting conditions requiring similar urgent care levels. The patient cohort, predominantly experiencing the HbSS genotype—the most severe variant—featured a median age of 33 and a high self-reported pain rating of nine out of ten at triage. Intriguingly, only 34.8% of visits were assigned an ESI score of 2, while the majority, 65.2%, received a less urgent ESI 3 designation. This discrepancy likely contributed to substantial delays in pain management.

Analysis revealed a stark contrast in the median time to first analgesic administration between patients accorded with the recommended ESI 2 and those triaged with ESI 3. Individuals classified as ESI 2 received their first dose after a median wait of 65 minutes, a timeframe still surpassing the NHLBI-recommended 60-minute target. By contrast, those assigned ESI 3 faced a median delay of 178 minutes—nearly triple the guideline threshold—with some patients leaving without receiving any pain medication after extended waiting times exceeding 300 minutes. These findings illuminate a glaring gap between recommended best practices and real-world emergency care delivery.

The ramifications of such delays in analgesic administration are particularly troubling given the excruciating nature of VOC pain. As noted by hematologist-oncologist Dr. Jennie Law, VOC episodes are frequently described by patients as the most intense pain of their lives, drawing comparisons to tightening a tourniquet on a limb. Effective and rapid pain control is not merely a comfort measure but a critical component of preventing the exacerbation of ischemic injury and subsequent morbidity. Delays can compound suffering and may lead to adverse patient outcomes, including increased risk of hospital admission and longer inpatient stays.

This study’s design, while rigorous, is not without limitations. Conducted at a single urban tertiary care hospital, its generalizability to other settings remains to be validated, especially in rural or less resourced emergency departments. Additionally, by calculating time to analgesia from triage rather than arrival, the analysis potentially underestimates total waiting periods experienced by patients. Nonetheless, the internal consistency of the data firmly supports the conclusion that inappropriate ESI assignment is a pivotal factor influencing treatment delays.

The research team proposes future investigations with larger, multi-center cohorts to corroborate these findings and explore the broader impact of ESI scoring on patient satisfaction and hospitalization metrics. There is anticipation that such evidence could galvanize policy revisions and resource allocation aimed at streamlining and standardizing VOC management protocols. Furthermore, integrating facility-level quality measures specific to sickle cell VOC management into national health metrics, as advocated by the ASH in partnership with the Health Services Advisory Group, may further enhance accountability and care quality.

Despite the advocacy efforts, these critical quality measures were not incorporated into the proposed FY 2025 Hospital Inpatient Prospective Payment System rule. This exclusion underscores the ongoing challenges in translating research insights into policy and practice improvements. Continued collaboration among clinicians, researchers, and policymakers is imperative to surmount these hurdles and ensure that all patients with sickle cell disease receive equitable, timely, and evidence-based emergency care.

From a clinical perspective, this study illuminates a simple yet impactful intervention: assigning the appropriate ESI score of 2 can dramatically reduce the time to first analgesia—a small procedural change with potential far-reaching benefits. Emergency department staff training and protocol adjustments to align with established guidelines could be pivotal steps toward improving care delivery and patients’ overall emergency department experience.

Moreover, this research brings to light the broader issue of systemic barriers affecting sickle cell disease management, including potential biases and misconceptions in clinical assessment that might contribute to under-triage. Addressing these factors requires comprehensive educational initiatives and institutional commitment to equity in healthcare provision.

In conclusion, as the burden of sickle cell disease continues to affect tens of thousands of Americans, refining emergency care strategies, particularly in pain crisis management, remains paramount. This groundbreaking study offers compelling evidence that adherence to established triage guidelines can markedly enhance the timeliness of pain relief for patients enduring VOC, providing a critical foundation for ongoing efforts to optimize emergency department care for this often underserved population.

—

Subject of Research: The impact of Emergency Severity Index (ESI) assignment on time to pain medication administration in patients with sickle cell disease presenting with vaso-occlusive crisis in emergency departments.

Article Title: Use of Emergency Severity Index 2 Reduces Time to First Analgesia in Sickle Cell Disease Vaso-occlusive Crisis

News Publication Date: October 8, 2025

Web References:
– https://doi.org/10.1182/bloodadvances.2025016538
– https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease
– http://www.bloodadvances.org/
– http://www.hematology.org/

Sickle cell disease, a genetic blood disorder, is notoriously challenging to manage due to its complex clinical manifestations and the unpredictability of painful flare-ups, known as sickle cell crises. These crises can be triggered by factors such as dehydration, infection, or significant physiological changes. Pain management in these situations typically revolves around medications, which often come with a myriad of side effects and significant potential for abuse. Therefore, alternative therapeutic avenues are crucial for enhancing quality of life amongst patients.

In this observational study, a diverse cohort of patients suffering from sickle cell disease was introduced to VR technology as a component of their pain management strategy. Participants were engaged in immersive VR environments designed to distract them from their pain and provide an escape into soothing and enjoyable experiences. These virtual platforms were not merely tools for distraction; they were carefully crafted experiences aimed at creating a psychological buffer against pain while allowing patients to engage fully with the therapeutic process.

Initially, the participants reported their pain levels and preferences for various virtual environments. The engagement with these digital landscapes, ranging from serene natural settings to interactive games, provided valuable insights into individual responses to VR as a pain management strategy. By understanding the specific virtual experiences that resonated most with individuals, clinicians could tailor intervention plans to optimize pain relief.

As participants navigated through these virtual realms, their pain was not the only thing that was being assessed. The study also observed the psychological and emotional responses elicited by VR engagement. Many participants reported feelings of joy and relaxation, which are often elusive emotions during intense pain crises. These positive emotional states can stimulate the release of endorphins, the body’s natural painkillers, which contributes to an overall reduction of the perceived pain levels.

During the study, researchers meticulously monitored the correlation between changes in pain levels and the extent to which participants engaged with the VR technology. Preliminary findings indicated that patients who expressed a higher level of immersion reported significantly reduced pain intensity. Moreover, they were found to require fewer pain medications during and after VR sessions, suggesting that technology can play an essential role in managing chronic pain.

The data collected from this initial phase of research provides tantalizing prospects for the broader application of VR technology in medical practices, especially in pain management protocols. With real-time feedback and interactive elements, VR can redefine how patients perceive pain. The aspect of interactivity gives a sense of control that is often lost when enduring chronic conditions, imbuing patients with a renewed sense of agency over their wellness management.

Additionally, another layer of complexity was added by examining the potential long-term impacts of this approach. Could regular VR interventions lead to decreased pain sensitivity over time, shifting the health landscape for individuals with sickle cell disease? While the preliminary outcomes are promising, further studies and longitudinal analysis will be required to determine the lasting effects of such technology on pain perception and overall wellbeing.

As the research progresses, it is vital to consider the accessibility of these virtual interventions. While the technology is rapidly advancing, ensuring that all patients, regardless of socioeconomic status, have equal access to such pain management tools is a chief concern. Researchers emphasize the need for collaboration with institutions that focus on equitable healthcare to bridge these gaps and bring innovative solutions to those who need them most.

Virtual reality as a therapeutic tool extends beyond simply entertaining patients. The compelling merger of cutting-edge technology with the need for comprehensive pain management strategies represents a paradigm shift in medical treatment. Harnessing the immersive capabilities of VR, medical professionals could build multidimensional pain management programs that address not only the physical symptoms but also the psychosocial aspects associated with chronic pain conditions.

The implications of this study reach beyond just sickle cell disease. As researchers observe the potential for VR to mitigate pain, other chronic conditions with similar pain management challenges may also benefit. Conditions such as fibromyalgia, arthritis, and even post-operative pain could leverage these digital interventions to provide relief and improve patient experiences throughout their treatment protocols.

The future of pain management is here, and it is entangled with technological innovation. As ongoing research sheds more light on the effectiveness of VR interventions, it could usher in a new era where patients are equipped with more tools for their healing journey, allowing them to reclaim their lives from the shackles of pain. The study underscores a pivotal moment in healthcare, prompting the broader medical community to embrace and adapt to the changing landscapes of therapy.

As patients, healthcare professionals, and technology developers continue to join forces, the collective goal remains clear: to find effective strategies that alleviate pain and promote overall health and wellbeing. With each step forward, there remains a sense of hope that the integration of technology in healthcare could reshape the narrative of chronic illness, offering the promise of better days ahead.

Subject of Research: Virtual Reality in Pain Management for Sickle Cell Disease

Article Title: Virtual Reality as RESPITE: Relief Exploration for Sickle Pain Through Interventions Using Technology Engagement: A Hospital-Based Observational Study

Article References:

Vidyasagar, N., Nguyen, M., Bundy, A. et al. Virtual Reality as RESPITE: Relief Exploration for Sickle Pain Through Interventions Using Technology Engagement: A Hospital-Based Observational Study.
J GEN INTERN MED (2025). https://doi.org/10.1007/s11606-025-09812-z

Image Credits: AI Generated

DOI: 10.1007/s11606-025-09812-z

Keywords: Virtual Reality, Sickle Cell Disease, Pain Management, Behavioral Intervention, Healthcare, Technological Innovation.